Iron Supplements for Infants at Risk for Iron Deficiency

Area of Science:

• Neonatal Medicine
• Pediatric Hematology
• Clinical Practice Guidelines

Background:

• Existing professional society recommendations for iron dosing in preterm neonates lack standardization.
• Variations in iron dosing protocols can impact infant health outcomes, particularly in high-risk populations.

Purpose of the Study:

• To analyze a decade of iron dosing practices in at-risk neonates.
• To identify variations in iron administration timing and cessation.
• To develop standardized iron-dosing guidelines for preterm neonates.

Main Methods:

• Retrospective 10-year analysis of iron dosing in specific neonatal groups.
• Inclusion criteria: infants of diabetic mothers (IDM), small for gestational age (SGA), and very low birth weight (VLBW) neonates (<1500 g).
• Analysis of iron administration post-red cell transfusion and erythropoiesis-stimulating agent (ESA) use.

Main Results:

• Iron was administered to 11.8% of IDM, 9.8% of SGA, and 27.1% of VLBW neonates.
• Iron initiation occurred by day 14 in 20% and by 1 month in 63% of recipients.
• Supplemental iron was discontinued post-transfusion in 73% of cases; 33% of infants receiving ESA also received iron within 3 days.

Conclusions:

• Significant variability exists in current iron dosing practices for at-risk neonates.
• Standardized guidelines are necessary to ensure consistent and appropriate iron management.
• This study's findings and literature review informed the development of updated, standardized iron-dosing protocols.